Primary Care Research Unit of Mallorca, Balearic Health Service, Palma, Spain.
Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, 07120, Illes Balears, Spain.
BMC Cancer. 2021 Jun 7;21(1):676. doi: 10.1186/s12885-021-08418-y.
Information about survival by stage in bladder cancer is scarce, as well as about survival of non-invasive bladder cancer. The aims of this study are: 1) to find out the distribution of bladder cancer by stage; 2) to determine cancer-specific survival by stage of bladder cancer; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers.
Incident bladder cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry.
cases with code C67 according to the ICD-O 3rd edition with any behaviour and any histology, except lymphomas and small cell carcinomas. Cases identified exclusively through the death certificate were excluded. We collected the following data: sex; age; date and method of diagnosis; histology according to the ICD-O 3rd edition; T, N, M and stage at the time of diagnosis; and date of follow-up or death. End point of follow-up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Cases with benign or indeterminate behaviour were excluded for the survival analysis. Actuarial and Kaplan-Meier methods and Cox regression models were used for survival analysis.
One thousand nine hundred fourteen cases were identified. 14% were women and 65.4% were 65 years or older. 3.9% had no stage (benign or undetermined behaviour) and 11.5% had unknown stage. After MI, 37.5% were in stage Ta (non-invasive papillary carcinoma), 3.2% in stage Tis (carcinoma in situ), 34.3% in stage I, 11.7% in Stage II, 4.3% in stage III, and 9.0% in stage IV. Survival was 76% at 5 years. Survival by stage: 98% at stage Ta, 90% at stage Tis, 85% at stage I, 45% at stage II, 35% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage, but not sex, were associated with survival.
Bladder cancer survival vary greatly with stage, among both non-invasive and invasive cases. The percentage of non-invasive cancers is high. Stage, age, and histology are associated to survival.
膀胱癌的分期生存信息以及非浸润性膀胱癌的生存信息都很缺乏。本研究的目的是：1）了解膀胱癌的分期分布；2）确定膀胱癌的癌症特异性生存率；3）确定解释和预测生存率以及死于这些癌症的风险的因素。
通过马洛卡癌症登记处确定 2006 年至 2011 年间诊断出的膀胱癌病例。
根据 ICD-O 第 3 版，编码为 C67 的病例，行为任意，组织学任意，除外淋巴瘤和小细胞癌。仅通过死亡证明确定的病例被排除在外。我们收集了以下数据：性别；年龄；诊断日期和方法；根据 ICD-O 第 3 版的组织学；诊断时的 T、N、M 和分期；以及随访或死亡日期。随访终点为 2015 年 12 月 31 日。对分期未知的病例进行多次插补（MI）。用于生存分析的良性或不确定行为的病例被排除在外。使用生存分析的寿命表和 Kaplan-Meier 方法和 Cox 回归模型。
共确定了 1914 例病例。14%为女性，65.4%为 65 岁或以上。3.9%没有分期（良性或不确定行为），11.5%分期未知。MI 后，37.5%为 Ta 期（非浸润性乳头状癌），3.2%为Tis 期（原位癌），34.3%为 I 期，11.7%为 II 期，4.3%为 III 期，9.0%为 IV 期。5 年生存率为 76%。按分期的生存率：Ta 期为 98%，Tis 期为 90%，I 期为 85%，II 期为 45%，III 期为 35%，IV 期为 7%。Cox 模型显示，年龄、组织学和分期，但不是性别，与生存相关。
膀胱癌的生存情况因分期而异，包括非浸润性和浸润性病例。非浸润性癌症的比例很高。分期、年龄和组织学与生存有关。
